New animal study shows promise for development of Parkinson's disease drug

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

Parkinson's disease is the second most common , affecting 1% of the population over the age of 65. It is characterized by loss of (neurons) from the mid-brain which use the to help control voluntary movements. Investigators from NeuroNova AB, Stockholm, Sweden, the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, The Parkinson's Institute, Sunnyvale, CA, USA, and Motac Neuroscience Ltd, Manchester, UK, found that behavioral, tissue and in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB. This could offer an alternative strategy to restore function in PD.

"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," commented Anders Haegerstrand, MD, PhD, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden."It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."

More information: The article is "Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease" by Olof Zachrisson, Ming Zhao, Annica Andersson, Karin Dannaeus, Johan Häggblad, Ruben Isacson, Elisabet Nielsen, Cesare Patrone, Harriet Rönnholm, Lilian Wikstrom, Kristofer Delfani, Alison L. McCormack, Theo Palmer, Donato A. Di Monte, Michael P. Hill, Ann Marie Janson Lang, and Anders Haegerstrand. Journal of Parkinson's Disease. 1(1). DOI 10.3233/JPD-2011-0003

Related Stories

RXR activation -- hope for new Parkinson's disease treatment

date Dec 11, 2009

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, ...

New stem cell research unlocks unknown therapies

date May 21, 2009

New treatments for the devastating Parkinson's disease and ALS are in clinical studies in Sweden, thanks to breaking new stem cell research. This news was presented today by Dr. Jonas Frisen, Professor of stem cell research ...

Recommended for you

AAPM: Platelet-rich plasma offers short-term benefit

date 45 minutes ago

(HealthDay)—For patients with facet joint arthropathy, platelet-rich plasma (PRP) has a short-term positive impact, according to a study presented at the annual meeting of the American Academy of Pain Medicine, ...

Brittle bone disease: Drug research offers hope

date 4 hours ago

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.